Information Provided By:
Fly News Breaks for August 9, 2018
SGMO
Aug 9, 2018 | 09:14 EDT
Jefferies analyst Maury Raycroft believes current share levels offer an "excellent entry point" into Sangamo Therapeutics following the company's hemophilia A data. While early, the data is "looking good," Raycroft tells investors in a research note. He believes Sangamo is aiming for best-in-class versus first-to-market. Two clinical catalysts for Sangamo have now been substantially de-risked, Raycroft contends. He recommends buying the stock and keeps a $28 price target for the shares.
News For SGMO From the Last 2 Days
There are no results for your query SGMO